AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Bone Marrow TransplantationTransplantation, HomologousBone MarrowHematopoietic Stem Cell TransplantationTransplantation, AutologousGraft vs Host DiseaseLiver TransplantationBone Marrow CellsTransplantation ConditioningWhole-Body IrradiationKidney TransplantationTissue DonorsGraft SurvivalTransplantation ChimeraAnemia, AplasticLeukemiaHistocompatibility TestingBusulfanHeart TransplantationHistocompatibilityTransplantation, IsogeneicStem Cell TransplantationLung TransplantationGraft RejectionHematologic NeoplasmsImmunosuppressive AgentsTreatment OutcomeRecurrenceBone Marrow PurgingTransplantation ImmunologyCyclophosphamideHematopoietic Stem CellsOrgan TransplantationCombined Modality TherapyTime FactorsImmunosuppressionLeukemia, Myeloid, AcuteRetrospective StudiesHematopoiesisRemission InductionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHepatic Veno-Occlusive DiseaseBone Marrow DiseasesRadiation ChimeraPrecursor Cell Lymphoblastic Leukemia-LymphomaMice, Inbred C57BLSurvival AnalysisAcute DiseasePancreas TransplantationTransplantationGraft vs Host ReactionIslets of Langerhans TransplantationHLA AntigensLymphocyte DepletionCell TransplantationLeukemia, MyeloidCord Blood Stem Cell TransplantationCyclosporineLymphoma, Non-HodgkinLeukocyte TransfusionMyelodysplastic SyndromesHematologic DiseasesSevere Combined ImmunodeficiencyT-LymphocytesFollow-Up StudiesSurvival RateBone Marrow ExaminationPeripheral Blood Stem Cell TransplantationLiving DonorsGraft vs Leukemia EffectCytomegalovirus InfectionsActuarial AnalysisLymphocyte TransfusionGraft vs Tumor EffectChimeraAntilymphocyte SerumColony-Forming Units AssayTransplantation ToleranceDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsPostoperative ComplicationsMelphalanNuclear FamilyCarmustineCytarabineChimerismSkin TransplantationTransplantation, HeterotopicMultiple MyelomaLymphomaPrognosisLeukocyte CountGranulocyte Colony-Stimulating FactorTissue and Organ ProcurementPancytopeniaHeart-Lung TransplantationInfectionCell DifferentiationSpleen
RecipientsDonorClinicalComplicationsAllogeneic HSCTOutcomesTransplantsSevereHaematopoieticRelapseHematologyBlasts in the bone maChemotherapyMultiple myelomaAutologous hematopoieticRemissionGVHDOrganTherapiesSignificantlyProphylaxisLiverKidneyDonorsProcedureImmunosuppressiveMedianOverall SurvivalPediatric patientsMortalityIndicationsImmuneJournal of TransplantationBone marroPatients underwentPatientMalignanciesSurvivalAbnormalitiesTissueOrgansTissuesThalassemiaBlood
Recipients14
  • Nevertheless, diagnosis and management of perioperative complications of organ transplantation still plays a prominent role in determining the postoperative course of allograft recipients. (medscape.com)
  • Future developments in the field of organ transplantation, including newer immunosuppressive medications and xenograft, pluripotent stem cell and neural tissue transplantation, will further change the spectrum of neurologic and other complications in transplant recipients. (medscape.com)
  • In May 2010, the Sixty-third World Health Assembly adopted resolution WHA63.22,1 in which it endorsed the updated WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation and provided strategic directions to support progress in human organ, tissue and cell donation with the aim of maximizing the benefits of transplantation, meeting the needs of recipients, protecting donors and ensuring the dignity of all involved. (who.int)
  • Corneal disease (scarring or perforation) can be successfully addressed through transplantation in 80% of affected individuals.3 Tissue transplantation allows many recipients to return to economically productive lives and promotes their independence. (who.int)
  • All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy before the bone marrow transplant (depending on age). (nih.gov)
  • Recipients will also receive other drugs to prevent transplant rejection and other complications of transplantation. (nih.gov)
  • The findings of the team's study " RNA-seq of human T cells after hematopoietic stem cell transplantation identifies Linc00402 as a regulator of T cell alloimmunity ," published in Science Translational Medicine , suggest that inhibiting the RNA therapeutically might improve outcomes for transplant recipients. (genengnews.com)
  • To identify lncRNAs that regulate human donor T cells after clinical HSCT, we performed RNA sequencing on T cells from healthy individuals and donor T cells from three different groups of HSCT recipients that differed in their degree of major histocompatibility complex (MHC) mismatch. (genengnews.com)
  • The fact that at our center, FQ-P in allo-HSCT recipients was discontinued on 01.12.2018 allowed comparison of the outcomes in patients treated with and without such prophylaxis. (confex.com)
  • FQ-P omission in allo-HSCT recipients appears to be safe and its implementation could contribute to the preservation of intestinal microbiome diversity, potentially leading to improved post-transplant outcome. (confex.com)
  • The Centers for Disease Control and Prevention (CDC) published "Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation" in the October 20, 2000, issue of "MMWR Recommendations and Reports" (vol. 49, no. (immunize.org)
  • This comprehensive 147-page report offers guidelines for preventing opportunistic infections in hematopoietic stem cell transplant (HSCT) recipients. (immunize.org)
  • The guidelines were developed for use by HSCT recipients, their households and close contacts, transplant and infectious diseases physicians, HSCT center personnel, and public health professionals. (immunize.org)
  • Although considerable attention has been focused on how to prevent the detrimental Acute Graft-Versus-Host Disease (aGvHD) while protecting the desired Graft-Versus-Leukemia (GvL) effect, recipients remain susceptible to the other life-threatening post-transplantation complications, including Chronic GvHD (cGvHD), Intestinal GvHD (iGvHD), Transplantation-Related Mortality (TRM), and hematological relapse. (ommegaonline.org)
Donor18
  • It may take about a month for the donor stem cells in the bone marrow to begin to function fully. (epnet.com)
  • Multivariate analysis identified age greater than 20 years at HSCT, HSCT before 2000, and alternative donor source to be poor prognostic markers. (nih.gov)
  • Is bone marrow or peripheral blood better for unrelated donor HSCT? (nih.gov)
  • The donor cells will live in the recipient's bone marrow and make blood and immune system cells. (primaryimmune.org)
  • One way to treat certain cancers of the blood and immune system is to give a patient stem cells from the bone marrow of a donor whose genes are very similar but not identical to the patient s. (nih.gov)
  • To determine whether lupron improves immune system function after bone marrow transplantation from a donor with similarities in their immune cells (matched to each other). (nih.gov)
  • FLT will be used to image the immune system function in patients who have received bone marrow from the donor. (nih.gov)
  • Patients who are not in remission or who require a bone marrow donor search may receive chemotherapy first. (nih.gov)
  • In HSCT, donor-matched cells are infused into the bloodstream of sick patients and ultimately travel to the bone marrow. (medicalxpress.com)
  • Yet despite careful donor-recipient matching and use of immunosuppressive therapies following transplantation, some of the donor's immune cells may begin to attack the patient's tissues, which is called graft-versus-host disease. (medicalxpress.com)
  • First, they showed that genetic elimination of ICOS ligand production in donor-mouse bone marrow cells prior to transplanting them into recipient mice protected the recipient mice from GVHD-related death. (medicalxpress.com)
  • Children without a suitable closely HLA-matched related or unrelated donor (donors with more than nine out of 10 matching HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ loci), were eligible to receive haploidentical HSCT. (bvsalud.org)
  • Linc00402 was also increased in donor T cells from patients who underwent allogeneic cardiac transplantation and in murine T cells. (genengnews.com)
  • It is categorized into two significant subtypes: autologous, where a patient donates the marrow stem cells to themselves, and allogeneic, which is a complex process of bone marrow transplantation where a patient receives the stem cell graft from a healthy donor. (zenonco.io)
  • 2012). The allogenic bone marrow transplantation involves the process of stem cell transplantation where a stem cell donor is matched with their related siblings or any other family member who is closely related (haploidentical). (zenonco.io)
  • Treatment of a patient with severe cytomegalovirus (CMV) infection after haploidentical stem cell transplantation with donor-derived CMV-specific T cells. (uliege.be)
  • Publications describing outcomes of children with leukemia who underwent UCB transplants have compared them to those having received unrelated donor marrow transplants. (northwestern.edu)
  • We analyzed the HSCT outcomes and any of the NOD2 polymorphisms in either donor or recipient. (ommegaonline.org)
Clinical13
  • New clinical trial findings show that a therapeutic regimen involving transplantation of a person's own blood-forming stem cells can improve survival and quality of life for people with severe scleroderma, a life-threatening autoimmune disease. (nih.gov)
  • The clinical trial, called Scleroderma: Cyclophosphamide or Transplantation (SCOT), compared the safety and potential benefits of the two treatment regimens among 75 people with diffuse systemic sclerosis who had lung or kidney involvement. (nih.gov)
  • Two previous clinical trials suggested HSCT benefited people with severe scleroderma. (nih.gov)
  • Participants in the SCOT trial, conducted at 26 clinical research sites in the United States and Canada, were randomly assigned to receive either myeloablative autologous HSCT or one year of treatment with monthly doses of intravenous cyclophosphamide. (nih.gov)
  • The Akari management team will present an overview of nomacopan and an update on the two registrational Phase 3 clinical trials investigating nomacopan as a potential treatment option for pediatric and adult HSCT-TMA. (woodtv.com)
  • Akari's pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). (woodtv.com)
  • Akari's pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com. (woodtv.com)
  • Therefore, immune injury caused by rejection remains an urgent problem to be solved and limits further clinical application of stem cell transplantation. (biomedcentral.com)
  • The findings of this study are beneficial to promote the clinical applications of stem cell transplantation and to provide some insights for transplantation tolerance. (biomedcentral.com)
  • Clinical responses were evaluated by the use of bone marrow aspiration, imaging, and flow cytometry. (e-crt.org)
  • Areas related to clinical and experimental transplantation are also of interest. (lidsen.com)
  • This Clinical Policy Bulletin addresses hematopoietic cell transplantation for non-hodgkin's lymphoma. (aetna.com)
  • Recent basic and clinical studies have deepened our understanding of the mechanisms of the immunological sequelae of HSCT, GVHD, and compromised immune systems. (apbmt.org)
Complications10
  • Ocular complications are common in children who undergo hematopoietic stem cell transplantation (HSCT), but most appear to be mild and have no long-term serious outcomes, according to data published online today in JAMA Ophthalmology . (medscape.com)
  • Neurologic complications are related to the surgical procedure of transplantation, posttransplant immunosuppression, opportunistic infection, or the inherent disorders that led to transplantation. (medscape.com)
  • The variety of conditions that led to organ failure requiring transplantation may also be associated with neurologic complications, including amyloid and diabetic neuropathy. (medscape.com)
  • Neurologic complications of organ transplantation occur internationally with a similar frequency as in the United States. (medscape.com)
  • Consider the onset of symptoms in relation to pretransplant neurologic status, to transplantation procedure, and to the current status of the transplanted allograft because the spectrum of complications changes over time and is influenced by a multitude of factors. (medscape.com)
  • HSCT for dyskeratosis congenita is characterized by a marked decline in long-term survival because of late deaths from pulmonary complications. (nih.gov)
  • The aim of this meta-analysis was to investigate NOD2 (nucleotide-binding oligomerisation domain containing 2) polymorphisms as possible susceptibility loci for GvHD as well as other life-threatening complications following HSCT. (ommegaonline.org)
  • Available studies addressing a possible contribution of NOD2 polymorphisms to GvHD and complications following HSCT were identified through database searches. (ommegaonline.org)
  • Gynaecological complications in HSCT women represent a serious concern for these patients, but often underestimated by clinicians in the view of Overall Survival. (unisa.it)
  • The main gynaecological complications of HSCT are represented by: premature ovarian failure (POF), thrombocytopenia-associated menorrhagia, genital symptoms or sexual problems in course of chronic GVHD (cGVHD), osteoporosis, secondary solid tumours due to immunosuppressive drugs to treat cGVHD and severity of cGVHD, and fertility and pregnancy issues. (unisa.it)
Allogeneic HSCT14
  • Transplantation strategy in these patients includes allogeneic HSCT or autologous gene-modified stem cell transplants. (nih.gov)
  • 11. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. (nih.gov)
  • The recommended dose of TEPADINA for class 3 beta-thalassemia is two administrations of 5 mg/kg given intravenously approximately 12 hours apart on Day -6 before allogeneic HSCT in conjunction with high-dose busulfan and cyclophosphamide. (nih.gov)
  • Allogeneic HSCT can also be considered for other forms of PI. (primaryimmune.org)
  • An allogeneic HSCT can replace an individual's own hematopoietic stem cells with stem cells that will produce functioning immune system cells. (primaryimmune.org)
  • If an allogeneic HSCT is successful, the donor's hematopoietic stem cells will replace the recipient's own cells. (primaryimmune.org)
  • Allogeneic HSCT also fixes any problems with other blood cells. (primaryimmune.org)
  • For example, platelets will be fixed in those with WAS who have a successful allogeneic HSCT. (primaryimmune.org)
  • Allogeneic HSCT remains the only validated treatment to cure leukemia," explained Paczesny, chairwoman of the MUSC Department of Microbiology and Immunology. (medicalxpress.com)
  • Approximately 50% of the transplants in case of acute myeloid leukaemia and ALL account for allogeneic HSCT. (zenonco.io)
  • Other indications for allogeneic HSCT include lymphoma, myeloma, and hematologic disorders like aplastic anaemia and thalassemia. (zenonco.io)
  • Methods Medically stable, paediatric allogeneic HSCT patients (n=23, ages 6-16 years) underwent an outpatient MRI scan where regional ventilation was quantified with a breath-hold of hyperpolarised 129 Xe gas. (ersjournals.com)
  • Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab? (unibas.ch)
  • Allogeneic HSCT is associated with severe immune compromise, with defects in both innate and adaptive immunity. (apbmt.org)
Outcomes10
  • Outcomes of corneal transplantation in Europe: report by the European Cornea and Cell Transplantation Registry. (who.int)
  • Standard annual reports (US Patient Survival Report, Current uses and outcomes of HSCT etc. (nih.gov)
  • More profound disease control or rare curative outcomes can currently only be expected after a consolidating allogeneic hematopoietic stem cell transplantation (allo-HSCT) in best first response. (springermedizin.de)
  • Series on allo-HSCT in T-PLL, although of very heterogeneous character, suggest a slight improvement in outcomes among transplanted patients within the past decade. (springermedizin.de)
  • Thus, haplo-HSCT can be a therapy option for these patients, and MRD status pre-HSCT significantly affects the outcomes. (bvsalud.org)
  • As patients with non-DS-AMKL have extremely poor outcomes, even with haplo-HSCT, a combination of novel therapies is urgently needed. (bvsalud.org)
  • Measurable residual disease (MRD) positivity before haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an independent prognostic factor in determining outcomes in patients with B-cell acute lymphoblastic leukemia (ALL). (bvsalud.org)
  • In this study, we define risk factors and describe the early and late outcomes of 169 patients with globoid cell leukodystrophy, X-linked adrenoleukodystrophy, and metachromatic leukodystrophy undergoing cord blood transplantation (CBT) at an European Society for Blood and Marrow Transplantation center or at Duke University Medical Center from 1996 to 2013. (uu.nl)
  • NOD2 polymorphism confers the more negative outcomes following HSCT. (ommegaonline.org)
  • During recent years, many studies have provided convergent lines of evidence for a link between Single Nucleotide Polymorphisms (SNPs) from specific genes and HSCT outcomes [2] . (ommegaonline.org)
Transplants2
Severe5
  • The benefits of human tissue transplantation can be seen in both children and adults, including in survival rates following severe burn trauma, recovery of movement, closure of chronic wounds, rehabilitation of heart function and restoration of sight. (who.int)
  • TEPADINA may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. (nih.gov)
  • Fewer than 2 percent of patients develop severe hepatic VOD after HSCT, but as many as 80 percent of patients who develop severe hepatic VOD do not survive. (fda.gov)
  • Based on published reports and analyses of patient-level data, the expected survival rates 100 days after HSCT would be 21 to 31 percent for patients with severe hepatic VOD who received only supportive care or interventions other than Defitelio. (fda.gov)
  • Since than much progress has been made and nowadays Hematopoietic Stem Cell Transplantation (HSCT) is considered the most effective treatment of numerous severe haematological diseases. (unisa.it)
Haematopoietic7
  • 1. Haematopoietic stem cell transplantation (HSCT) in Europe 2002. (nih.gov)
  • 3. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. (nih.gov)
  • 10. Haematopoietic stem cell transplantation in children in eastern European countries 1985-2004: development, recent activity and role of the EBMT/ESH Outreach Programme. (nih.gov)
  • 14. Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. (nih.gov)
  • Data from 200 children with high-risk acute myeloid leukaemia who underwent their first haploidentical haematopoietic stem cell transplantation (haplo-HSCT) between 2015 and 2021 at our institution were analysed. (bvsalud.org)
  • Haematopoietic stem cells (HSCs) are adult stem cells that represent almost 0.05 to 0.5% of the cellular density of the normal bone marrow. (zenonco.io)
  • Background Early detection of pulmonary morbidity following haematopoietic stem cell transplantation (HSCT) remains an important challenge for intervention, primarily due to the insensitivity of spirometry to early change, and in paediatrics, patient compliance provides additional challenges. (ersjournals.com)
Relapse8
  • In the case of relapse after transplantation, the prognosis is dismal. (ahdbonline.com)
  • In this context, pathway inhibitors could be promising in the context of lowering the bulky leukemic cells before proceeding to allo-HSCT as well as when used after transplantation to treat or prevent disease relapse. (ahdbonline.com)
  • Patients received ibrutinib for relapse after allo-HSCT (n = 27, median time from allo-HSCT to progression: 22 months), 1 for stable disease and 2 after positive minimal residual disease. (ahdbonline.com)
  • The authors concluded that ibrutinib can be safely administered for CLL/MCL relapse after allo-HSCT, with efficacy that is at least similar to nontransplanted patients with high-risk disease. (ahdbonline.com)
  • Although relapse is mainly detected in bone marrow, occasionally extramedullary tissues are involved and these account for 15%-20% of all relapses [ 3 ]. (e-crt.org)
  • Minimal residual disease (MRD)-positive (MRD+) status pre-HSCT was significantly associated with lower survival and a higher risk of relapse. (bvsalud.org)
  • The median time to relapse post HSCT was 2.1 months (range: 1.0-14.4 months). (bvsalud.org)
  • Chronic GVHD is also a major cause of late non-relapse mortality (NRM) after HSCT and significantly impairs the quality of life of the transplant survivors 1 . (apbmt.org)
Hematology2
  • The approval of Defitelio fills a significant need in the transplantation community to treat this rare but frequently fatal complication in patients who receive chemotherapy and HSCT," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. (fda.gov)
  • This retrospective single-center study included all consecutive patients, admitted to the Rambam Department of Hematology for allo-HSCT between 01.01.2017 and 31.12.2019. (confex.com)
Blasts in the bone ma1
  • The diagnostic criteria of AMKL without DS were adapted from the FAB and WHO: ≥ 20% blasts in the bone marrow, and those blasts expressed at least one or more of the platelet glycoproteins: CD41, CD61, or CD42. (bvsalud.org)
Chemotherapy10
  • The regimen, known as myeloablative autologous hematopoietic stem cell transplant (HSCT), includes chemotherapy and total body radiation to destroy the bone marrow followed by transplantation of the person's own blood-forming stem cells to reconstitute the marrow and immune system. (nih.gov)
  • Participants in these earlier trials received non-myeloablative HSCT, a less intensive procedure using lower doses of chemotherapy that does not completely destroy the bone marrow. (nih.gov)
  • The procedure began with doctors collecting a participant's blood-forming stem cells, after which the participant received chemotherapy and radiation to eliminate the bone marrow. (nih.gov)
  • Immediately before an HSCT procedure, a patient receives chemotherapy. (fda.gov)
  • Hepatic VOD can occur in patients who receive chemotherapy and HSCT. (fda.gov)
  • Surgical resection of the IV rib and intensive chemotherapy led to a complete morphological remission, and allogeneic bone marrow transplantation was performed. (frontiersin.org)
  • We describe the case of a mantle cell lymphoma patient who developed a fulminant hepatitis following oxaliplatin-containing intensive chemotherapy and autologous transplantation. (biomedcentral.com)
  • Conventional chemotherapy, radiation, or even allogeneic hematopoietic stem cell transplantation (allo-HSCT) tend to be unsuccessful in these patients, especially those with multiple relapses [ 7 , 8 ]. (e-crt.org)
  • In this study, we conducted a parallel comparison of the efficacy and safety in patients with suboptimal MRD response after reinduction who underwent haplo-HSCT after chimeric antigen receptor T-cell (CAR-T) therapy or chemotherapy. (bvsalud.org)
  • Stem cells are mobilised from the bone marrow and then harvested and frozen, to be then reinfused into the same patient after their immune system has been almost completely eliminated by chemotherapy. (iflscience.com)
Multiple myeloma1
Autologous hematopoietic5
  • Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (SOS/VOD), is a potentially fatal complication of allogeneic or autologous hematopoietic stem cell transplantation. (biomedcentral.com)
  • In the last two decades, a type of stem cell transplantation has received considerable attention as an experimental treatment for MS. Called autologous hematopoietic stem cell transplantation (HSCT), this method involves harvesting and freezing stem cells from bone marrow which are then reinfused into the patient. (iflscience.com)
  • Aetna considers autologous hematopoietic cell transplantation for the treatment of persons with relapsed or primary refractory (see "Note" below) non-Hodgkin's lymphoma (NHL) medically necessary if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
  • Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of persons with relapsed NHL (including persons who have relapsed after autologous hematopoietic cell transplantation) or primary refractory (see "Note" below) NHL (low-grade, intermediate-grade, and high-grade) if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
  • Aetna considers tandem autologous hematopoietic cell transplantion (auto-auto) or tandem autologous hematopoietic cell transplantation followed by allogenic hematopoietic cell transplantation (auto-allo) experimental and investigational for NHL due to a lack of adequate evidence in the peer-reviewed published medical literature of their safety and effectiveness. (aetna.com)
Remission2
  • For patients relapsing after CAR-T, a second CAR-T therapy creates another opportunity for remission for subsequent HSCT. (e-crt.org)
  • Several researchers have regarded pediatric AMKL without DS as high-risk or at least intermediate-risk AML and proposed that upfront allogenic hematopoietic stem cell transplantation (HSCT) in first complete remission might improve long-term survival. (bvsalud.org)
GVHD9
  • A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D., Ph.D., sheds light on immune cell biomarkers that may reveal which patients are most at risk for graft-versus-host disease (GVHD), a life-threatening condition that can arise after hematopoietic stem cell transplantation (HSCT) for treatment of liquid cancers such as leukemia. (medicalxpress.com)
  • GVHD impacts up to 50% of patients receiving HSCT and can manifest in multiple organs. (medicalxpress.com)
  • In this way, individuals who are actively developing symptoms of GI-GVHD following HSCT could potentially be flagged. (medicalxpress.com)
  • Susceptibility to Graft-Versus-Host Disease (GvHD) following Hematopoietic Stem Cell Transplantation (HSCT) has been linked to the NOD2 gene, but results have been so far conflicting among individual studies. (ommegaonline.org)
  • Effective control of the graft-versus-host disease (GVHD) and immune reconstitution are crucial in improving the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) as well as the quality of life of the transplant survivors. (apbmt.org)
  • Graft-versus-host disease (GVHD) is a major devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT). (apbmt.org)
  • Acute GVHD develops early after HSCT, typically within 100 d post-transplantation. (apbmt.org)
  • Therefore, immunosuppression alone may be insufficient to control GVHD after HSCT. (apbmt.org)
  • Recent insights into intestinal homeostasis after HSCT have greatly reconciled our understanding of GVHD pathophysiology and helped reshape contemporary GVHD prophylaxis and treatment strategies. (apbmt.org)
Organ8
  • Organ transplantation has developed at an incredibly rapid pace since its introduction in the 1950s, and it has become a life-saving procedure for patients with end-stage organ failure. (medscape.com)
  • In 2009, more than 20,000 hematopoietic stem cell transplantations and 27,000 solid organ transplantations were performed in the United States alone. (medscape.com)
  • Organ transplantation may also improve neurologic function in various disorders with neurologic manifestations such as Wilson disease (liver transplantation), familial amyloidosis with neuropathy (liver transplantation), and diabetic neuropathy (pancreas transplantation). (medscape.com)
  • Organ transplantation is often the best, if not the only, treatment for acute and chronic organ failure. (who.int)
  • A long noncoding RNA whose function was previously unknown turns out to play a vital role in mobilizing the immune response following a bone marrow transplant or solid organ transplantation, according to researchers at the University of Michigan (U-M) Rogel Cancer Center and Michigan Medicine. (genengnews.com)
  • Mechanisms governing allogeneic T cell responses after solid organ and allogeneic hematopoietic stem cell transplantation (HSCT) are incompletely understood. (genengnews.com)
  • Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores. (uliege.be)
  • Generation of reliable data and ability to extend the typing to additional loci will allow providing better patient care not only in HSCT, but also in organ transplantation. (omixon.com)
Therapies1
  • The present report aims to provide a comprehensive analysis of the current situation and facilitate a forward-looking discussion on actions for improving access to transplantation therapies. (who.int)
Significantly3
  • Compared with cyclophosphamide, transplantation offered significantly greater long-term benefits, but also carried known short-term risks, such as infections and low blood cell counts. (nih.gov)
  • FQ-P omission has not significantly increased the rate of GNB-BSI or affected the profile of GNB susceptibility to antibiotic treatment in patients undergoing allo-HSCT. (confex.com)
  • Hematopoietic stem cell transplantation (HSCT) or Bone Marrow Transplantation (BMT) has significantly improved the survival rates of patients suffering from hematological malignancies. (lidsen.com)
Prophylaxis2
  • Another option may be routine use of androgen after HSCT for the prophylaxis of pulmonary fibrosis. (nih.gov)
  • Fluoroquinolone prophylaxis (FQ-P) is demonstrated to reduce the rate of blood stream infections (BSI) caused by gram-negative bacteria (GNB) during allo-HSCT and increases overall survival (OS), making this approach the standard of care. (confex.com)
Liver4
  • For chronic or acute liver failure, as well as some cardiorespiratory conditions, the only alternative to transplantation is death. (who.int)
  • The patients enrolled in all three studies had a diagnosis of hepatic VOD with liver or kidney abnormalities after HSCT. (fda.gov)
  • Over time, excessive storage of fats can cause permanent cellular and tissue damage, particularly in the brain, peripheral nervous system (the nerves from the spinal cord to the rest of the body), liver, spleen, and bone marrow. (nih.gov)
  • Niemann-Pick disease is a group of autosomal recessive disorders caused by an accumulation of fat and cholesterol in cells of the liver, spleen, bone marrow, lungs, and, in some instances, brain. (nih.gov)
Kidney3
Donors1
Procedure5
  • This procedure is done if the stem cells in your bone marrow are not functioning or are deficient. (epnet.com)
  • HSCT offers the only potential for a cure for many hematologic cancers, and success and survival rates after this procedure in children continue to improve. (medscape.com)
  • HSCT is a procedure performed in some patients to treat certain blood or bone marrow cancers. (fda.gov)
  • Our comprehensive guide to HSCT covers patient preparation, the procedure itself, and what to expect afterward. (primaryimmune.org)
  • Bone marrow transplantation is considered an effective procedure for treating different cancer types. (zenonco.io)
Immunosuppressive1
  • Early after transplantation, the use of a higher dose of immunosuppressive medications predisposes patients to their neurotoxicity. (medscape.com)
Median3
  • Diagnosis was CLL in 27 (90%) patients and MCL in 3 patients, with a median number of treatment lines prior to transplantation of 3. (ahdbonline.com)
  • Prior to allo-HSCT, 4 patients (2 CLL and 2 MCL) had received an auto-HSCT and 4 other CLL patients had been exposed to ibrutinib for a median of 261 days. (ahdbonline.com)
  • Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a life-threatening complication [ 1 ] following hematopoietic stem cell transplantation (HSCT) with median incidence lower than 10% after autologous HSCT [ 2 ]. (biomedcentral.com)
Overall Survival1
  • The studies measured the percentage of patients who were still alive 100 days after HSCT (overall survival). (fda.gov)
Pediatric patients2
Mortality2
  • The mortality rate of P. jirovecii pneumonia (PCP) in these patients is 30%-60%, especially after HSCT. (unl.pt)
  • The available data show that during the transplantation period, the intestinal microbiome diversity profoundly decreases, which is associated with a significant increase in transplant-related mortality (TRM), acute graft-versus-host disease (aGVHD) related mortality and decrease in OS. (confex.com)
Indications2
  • Other indications for autologous HSCT include autoimmune diseases such as multiple sclerosis, systemic sclerosis, and Crohn's disease and solid tumors such as sarcoma, germinal tumors, and neuroblastoma. (zenonco.io)
  • Bone marrow transplantation is employed for novel indications in treating autoimmune and inherited metabolic disorders (Daikeler et al. (zenonco.io)
Immune7
  • NIH-funded study finds transplantation superior to treatment with immune-suppressing drug. (nih.gov)
  • The study, funded by the National Institutes of Health, found myeloablative HSCT to be superior to treatment with the immune-suppressing drug cyclophosphamide. (nih.gov)
  • Finally, doctors infused the participant's own blood stem cells to rebuild the bone marrow and a normally functioning immune system. (nih.gov)
  • The webinar event will feature Sonata Jodele, MD, Research Professor in the Division of Bone Marrow Transplantation and Immune Deficiency at the University of Cincinnati Department of Pediatrics and Professor Rob Wynn of Royal Manchester Children's Hospital, part of Manchester University NHS Foundation Trust. (woodtv.com)
  • Immune system cells develop from special cells that live in the bone marrow called hematopoietic stem cells. (primaryimmune.org)
  • Hematopoietic stem cell transplantation (HSCT) involves the regeneration of haematopoiesis, and the recipient's immune system is found within the bone marrow. (zenonco.io)
  • It helps increase the bone marrow function that depends upon the treatment of the disease in eliminating the tumor cells with malignancy or generating the functional cells that replace the dysfunctional cells in certain disorders such as immune deficiency syndromes, hemoglobinopathies, and other diseases. (zenonco.io)
Journal of Transplantation2
Bone marro3
Patients underwent2
  • During the evaluated period, 189 patients underwent allo-HSCT and were included in the analysis. (confex.com)
  • In all, 23 patients underwent allogeneic-related HSCT and 26 underwent UCB transplantation. (northwestern.edu)
Patient7
Malignancies2
  • Pneumocystis jirovecii can cause life-threatening pneumonia following treatment for haematological malignancies or after HSCT. (unl.pt)
  • In today's era, bone marrow transplantation has become standard care for hematologic malignancies and congenital or acquired disorders of the hematopoietic system. (zenonco.io)
Survival2
  • The recent systematic review of the literature showed poor long-term outcome, with 10-year survival estimates of only 23% in 109 patients with dyskeratosis congenita who received HSCT. (nih.gov)
  • Does FLT3 mutation impact survival after HSCT for AML? (nih.gov)
Abnormalities2
  • The researchers, led by Viera Kalinina Ayuso, MD, from the University Medical Center Utrecht, the Netherlands, recommend that all children be screened before undergoing HSCT to look for ocular abnormalities that could require prophylactic treatment. (medscape.com)
  • Regional lung ventilation abnormalities in paediatric HSCT patients were quantified using hyperpolarised xenon-129 ( 129 Xe) magnetic resonance imaging (MRI) and compared to spirometry. (ersjournals.com)
Tissue2
  • MSCs reside through the entire physical body and will end up being extracted from a number of tissue including bone tissue marrow, adipose tissues, gingiva, oral pulp, and tonsil, aswell as in the immature tissue including amniotic liquid, placenta, and umbilical cable or cord bloodstream. (bibf1120.com)
  • These sources include bone marrow, fat (adipose tissue), umbilical cord tissue (Wharton's Jelly), and amniotic fluid in humans (the fluid surrounding a fetus). (onestopthai.com)
Organs3
  • 1] . Complex multiorgan failure may require simultaneous transplantation of several organs. (medscape.com)
  • The transplantation of human tissues, organs or cells is an established form of treatment that has been acknowledged as the best and very often only life-saving therapy for several serious and life-threatening congenital, inherited and acquired diseases and injuries. (who.int)
  • In June 2018, the Secretariat established the WHO Task Force on Donation and Transplantation of Human Organs and Tissues as an advisory group composed of experts from all WHO regions. (who.int)
Tissues1
Thalassemia2
  • Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. (cdc.gov)
  • Some involve leukaemias, bone marrow failures, hemoglobinopathies (thalassemia, sickle cell disease), immunodeficiencies, and other HSC transplant-based treatments for solid tumors and other genetic disorders such as lysosomal storage disease along with autoimmunity. (zenonco.io)
Blood8
  • 4. Blood and marrow transplantation activity in Europe 1996. (nih.gov)
  • European Group for Blood and Marrow Transplantation (EBMT). (nih.gov)
  • 5. Blood and marrow transplantation activity in Europe 1997. (nih.gov)
  • 6. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. (nih.gov)
  • Patients included in this study were those who had been registered with the European Society for Blood and Marrow Transplantation (EBMT) for an allo-HSCT for CLL or MCL and who received ibrutinib for disease recurrence or persistence at any time after transplant. (ahdbonline.com)
  • T-PLL patients typically present with exponentially rising blood lymphocyte counts, bone marrow infiltration, splenomegaly, and small lymphadenopathy. (springermedizin.de)
  • Protocols for transplantation have been refined over the years, learning from those used in the treatment of certain blood cancers, which has led to reduced toxicity and fewer deaths using the technique . (iflscience.com)
  • Biology of Blood and Marrow Transplantation. (elsevierpure.com)